Regeneron’s Fianlimab Flop Rewrites the LAG-3 Playbook — and Bristol-Myers Just Got Luckier
Regeneron's Phase 3 fianlimab trial misses in first-line melanoma, threatening a key pipeline asset and handing Opdualag a competitive...
LAG-3 inhibitor
Regeneron's Phase 3 fianlimab trial misses in first-line melanoma, threatening a key pipeline asset and handing Opdualag a competitive...